HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.

Abstract
Lonidamine, a derivate of indazole-3-carboxylic acid, is an antineoplastic drug with a typical mechanism of action. Lonidamine has no function on cellular nucleic acids or protein synthesis, whereas it exerts a powerful inhibitory effect on oxygen consumption, aerobic glycolysis and lactate transport and accumulation of neoplastic cells. Nevertheless, its proven ability to modify the permeability of membranes is consistent with the possible increase of drug uptake, reverse of drug resistance and triggering of apoptotic pathway. Lonidamine has been experimentally shown to potentiate the cytotoxic effects of anthracyclines in human breast cancer cell lines and cisplatin activity in both platinum-sensitive and platinum-resistant human ovarian carcinoma cell lines. Since the specific mechanism of action and side effects are not overlapping with those of standard antineoplastic agents, combination of lonidamine with standard chemotherapy has been widely investigated for the treatment of solid tumors. Additionally, the enhancement of radiotherapy activity by lonidamine has been considered for palliative therapy of lesions from metastatic cancers. The encouraging results of phase II-III trials for the treatment of advanced breast, ovarian and lung cancer must be confirmed by larger studies. Specifically designed studies to address the role of lonidamine in the adjuvant setting are warranted. Lonidamine, a dechlorinate derivative of indazole-3-carboxylic acid, has proved to exert a powerful antiproliferative effect and to impair the energy metabolism of neoplastic cells. Herein we review the current experience on combining lonidamine and chemotherapy and/or radiation therapy in the treatment of solid tumors. Several studies have been published on this topic. The total number of trials reported in literature and length of follow-up are still insufficient to draw a firm conclusion. However, the available data demonstrate a significant role of lonidamine in modulating anthracycline and platinum compound activity.
AuthorsSerena Di Cosimo, Gianluigi Ferretti, Paola Papaldo, Paolo Carlini, Alessandra Fabi, Francesco Cognetti
JournalDrugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 39 Issue 3 Pg. 157-74 (Mar 2003) ISSN: 1699-3993 [Print] Spain
PMID12730701 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Indazoles
  • lonidamine
Topics
  • Aged
  • Antineoplastic Agents (adverse effects, pharmacokinetics, therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Carcinoma, Non-Small-Cell Lung (drug therapy)
  • Clinical Trials as Topic
  • Female
  • Humans
  • Indazoles (adverse effects, pharmacokinetics, therapeutic use)
  • Lung Neoplasms (drug therapy)
  • Male
  • Ovarian Neoplasms (drug therapy)
  • Safety

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: